Alzheimer’s Disease
Alzheimer’s disease is a qualifying condition in Georgia’s Medical Cannabis Patient Registry. A Georgia-licensed physician reviews the diagnosis, medical history, and eligibility before deciding whether to certify a patient. A medical card is not evidence that cannabis will improve memory or alter the underlying disease.
$100 · Private 15-minute phone consultation with a Georgia-licensed physician. GMMC serves adults age 18 and older throughout Georgia.
Book on Calendly. Our team sends an eVisit link for the telemedicine visit. Payment is collected through eVisit after the visit. If our physician determines that the patient does not qualify for medical cannabis certification, we will refund any consultation fee paid. State card fees are separate.
Families often ask about agitation, sleep, appetite, anxiety, and daily comfort. This guide explains eligibility and research without promising a treatment outcome. Continue established dementia care and discuss any proposed cannabis use with the treating clinicians.
Does Alzheimer's Disease Qualify in Georgia?
The Georgia Department of Public Health’s current patient guidance lists Alzheimer’s disease among qualifying conditions. Its current list does not limit this condition to an end-stage diagnosis.
Certification is based on medical judgment. The physician must be fully licensed and have a principal practice location in Georgia. Booking an appointment or paying a fee does not guarantee certification or state enrollment.
Prepare available diagnosis records and the current medication list. The physician determines what documentation and evaluation are needed. GMMC serves adults statewide; contact the team before booking if communication or participation arrangements need discussion.
The state includes other conditions with separate criteria. See our Georgia qualifying conditions guide, including the distinction between intractable pain and general chronic pain.
Alzheimer's Disease and Other Dementias
Dementia describes problems with memory, thinking, or other mental abilities that interfere with everyday life. Alzheimer’s disease is one cause of dementia. Other dementias include vascular dementia and Lewy body dementia.
People living with dementia may need support with daily activities, communication, food, medication routines, and safety. Their diagnosis and care plan should come from their treating clinicians. New symptoms should not automatically be attributed to Alzheimer’s or treated through a website recommendation.
The National Institute on Aging’s dementia information provides resources for patients and caregivers. It can help families learn about diagnosis, treatment, and support.
Memory Loss, Behavioural Symptoms, and Psychological Symptoms
Memory loss and changes in thinking are different from behavioural symptoms such as agitation. Anxiety, mood changes, sleep problems, and other psychological symptoms may also affect daily life.
Research about one symptom cannot automatically establish benefit for another. Reduced agitation in a study does not prove restored memory, improved judgment, or prevention of dementia progression.
Tell the treating team about changes in behaviour, discomfort, sleep, appetite, and daily function. A careful review may identify other factors involved, including pain, illness, medication effects, or environmental stress.
Continue the Existing Care Plan
Keep established medical appointments and prescribed medications. A cannabis eligibility evaluation does not replace a neurologist, geriatrician, primary-care clinician, or dementia-care team.
Families can discuss routines, environmental adjustments, communication strategies, and other therapies with the treating team. Medication decisions should account for the person’s health, diagnosis, goals, and possible adverse effects.
If the patient has a sudden change in alertness or behaviour, seek appropriate medical assessment rather than assuming that an adjustment to cannabis will solve it.
What Clinical Trials Say About Medical Cannabis and Dementia
Researchers have investigated cannabinoids as a potential treatment for certain dementia symptoms. The evidence is developing, and the product, patient population, outcomes, and duration of a study all matter.
There is no established evidence that cannabis cures Alzheimer’s disease, restores lost memory, or prevents dementia. Laboratory findings and symptom studies should not be presented as proof of disease modification in humans.
Earlier Small Clinical Trials
A 2021 Cochrane review assessed four small trials involving 126 participants. It found substantial uncertainty about benefits and harms, with limited confidence in the evidence.
The reviewed studies were short and used different cannabinoids. Results about behavioural and psychological symptoms varied, and effects on memory and thinking were limited. This review predates newer trials, so it is useful historical context rather than a complete account of current research.
A small group showing improvement does not establish that all patients will respond. Long term effects and safety need appropriate follow-up.
New Research on Agitation: The LiBBY Trial
Topline findings reported at the 2026 Alzheimer’s Association International Conference described the Phase 2 LiBBY study. This randomized, placebo-controlled trial studied an oral THC/CBD formulation in 120 people with dementia who were receiving or eligible for hospice care and had significant agitation.
The report described greater reductions in agitation with the study treatment than with placebo during the 12-week trial. These are conference-reported topline results in a specific late-stage population, not proof of benefit for all people with Alzheimer’s disease.
The study was conducted through a National Institute on Aging-funded research consortium. Funded research and university involvement do not mean GMMC participated in the trial or provides the same intervention.
Research suggests a possible role worth discussing for this particular symptom and population. It does not show a cure, prevention of dementia, or restoration of cognition. The study formulation and supervision should not be equated with every cannabis oil available commercially.
This page does not reproduce the trial’s dosing schedule. Any consideration of treatment requires an individualized discussion with the patient’s treating team.
Reading Dementia Cannabis Claims Carefully
When a new study is reported, ask who participated, which product was tested, what changed, and whether adverse effects were measured. Distinguish a conference report from a full published analysis and a symptom outcome from a change in the disease itself.
Research projects involving cells or animals can explore mechanisms in the brain. They cannot establish that a product will treat dementia in a person. More evidence is needed about broader populations, product differences, and longer follow-up.
Claims from other countries, including references to Health Canada, do not determine Georgia eligibility, product rules, or the suitability of treatment for an individual.
THC, CBD, and the Endocannabinoid System
The cannabis plant contains cannabinoids, including THC and CBD. Scientists study cannabinoid receptors and the endocannabinoid system to understand effects on nervous-system signaling.
A mechanism proposed in a laboratory does not establish clinical benefit. Likewise, a synthetic form of a cannabinoid and a plant-derived commercial product can differ in composition and evidence.
THC can cause intoxication and changes in thinking or perception. CBD is not interchangeable with THC, and “non-intoxicating” does not mean free of side effects or medication interactions.
This page does not recommend a THC-to-CBD ratio, a best product, or a dose. High doses are not evidence of greater benefit, and even a small dose may be unsuitable for some patients.
Potential Risks for Older Adults
The NIH cannabis overview describes possible effects on memory, thinking, movement, and perception. Dizziness and drowsiness can matter for older adults, particularly when balance or daily function is already affected.
Confusion, sedation, anxiety, and other unwanted effects may complicate care. A person with dementia may have difficulty describing what they are experiencing, so caregivers should discuss observation and communication plans with clinicians.
Review all medications and supplements. Include sedating medicines, nonprescription products, and any cannabis already being used. The physician or pharmacist can assess the actual combination.
A change in behaviour after starting a product does not automatically mean it is beneficial. Discuss alertness, function, balance, appetite, and other relevant observations with the treating team.
Consent and Caregiver Participation
Caregiver registration and the patient’s ability to consent are separate questions. Helping with scheduling or holding a caregiver card should not be treated as blanket permission to make every treatment decision.
Tell the team before booking about communication needs, decision-making arrangements, and the person who will assist. The clinician can determine how the evaluation should proceed.
Follow DPH’s patient and caregiver guidance for registration. This website does not resolve legal authority for an individual family.
Preparing for an Alzheimer's Consultation
Prepare available diagnosis records and an up-to-date medication list. The physician decides which additional information is needed; families do not need to guess at a website’s complete test checklist.
Useful preparation includes:
Available records documenting Alzheimer’s disease and ongoing care
Current prescribed medications, supplements, and known allergies
Relevant history of previous cannabis use or adverse effects
Questions about eligibility, risks, and the state process
Current identity and Georgia residency documents
Information about communication or participation arrangements
Ask the team how to submit records securely. Do not send medical records, identity documents, or detailed symptoms through the public website contact form.
A concise list of questions helps both you and the clinician focus the consultation. Keep information accurate and include other conditions that may affect assessment.
How the GMMC Consultation and State Process Work
Book on Calendly: Select a private 15-minute phone consultation for an adult patient.
Receive the eVisit link: Our team sends the link for the telemedicine visit. Discuss appointment arrangements before booking when needed.
Attend the physician evaluation: The Georgia-licensed physician reviews the diagnosis, medical history, and eligibility.
Pay through eVisit after the visit: The consultation fee is $100. If our physician determines that the patient does not qualify, we will refund any consultation fee paid.
Complete state verification if certified: The physician submits required information to the registry. DPH verifies it and sends state payment instructions.
Receive the state card: Follow DPH delivery instructions and allow up to 10 business days after state payment processing.
GMMC provides the consultation service. DPH issues the state card. Certification and state enrollment are required; an online booking alone does not authorize possession of medical cannabis.
Fees, Card Validity, and Annual Certification
The state card fee is $30, with a $3.75 service fee when using DPH’s online payment portal. These fees are separate from GMMC’s $100 consultation and any dispensary purchases.
The Medical Cannabis Card is valid for five years. Annual physician certification is generally required; certification timing differs from card expiration. Georgia law exempts patients with incurable or irreversible conditions from annual certification. Confirm whether this applies to your documented condition and registry record with your certifying physician or Georgia DPH. Review the certification exception and card renewal.
Use current DPH instructions for identity, residency, payment, and delivery. Older Low THC Oil Registry materials may describe different procedures.
Georgia Product and Possession Guidance
DPH currently lists a possession limit of 12,000 milligrams of THC for registered patients and caregivers. That legal ceiling is not a dose recommendation or a measure of what is medically appropriate.
Consult the Georgia Access to Medical Cannabis Commission for current product restrictions and licensed dispensaries. Products or other forms available elsewhere should not be assumed to be permitted in Georgia.
A registry card does not authorize unrestricted cannabis possession or override federal law. State access and the individual medical decision remain different questions.
Frequently Asked Questions
Can Medical Marijuana Cure Alzheimer's Disease?
Cannabis has not been established as a cure, a way to restore memory, or a way to prevent dementia. Agitation research concerns symptom outcomes rather than reversal of the underlying disease.
Does Alzheimer's Have to Be End-Stage to Qualify?
DPH’s current qualifying conditions list includes Alzheimer’s disease without that restriction. The physician reviews the diagnosis and determines certification using medical judgment.
Can CBD Oil Alone Be Assumed to Help?
No. Products and research findings differ. A trial involving a THC/CBD formulation does not establish that CBD alone will produce the same result.
Can a Family Member Help With the Appointment?
Contact the team before booking to discuss communication and participation arrangements. Scheduling assistance, caregiver registration, and consent authority are distinct issues.
Does GMMC Provide Ongoing Dementia Treatment?
The certification consultation does not replace ongoing dementia care. Continue treatment and follow-up with the patient’s established clinicians.
When Is the Consultation Charged?
The $100 consultation fee is collected through eVisit after the visit. State card fees and any product purchases are separate.
What Happens if the Patient Does Not Qualify?
If our physician determines that the patient does not qualify for medical cannabis certification, we will refund any consultation fee paid. This is a service, with no merchandise to return.
Can a Website Identify the Safest Form or Dose?
No single formulation or dose is appropriate for everyone. A clinician must consider the individual’s medical history, medications, risks, and care goals.
Book an Adult Alzheimer's Consultation
If an adult patient has diagnosed Alzheimer’s disease and wants to discuss Georgia medical cannabis eligibility, gather available records and the medication list. Contact the team first if appointment arrangements need clarification.
$100 · Private 15-minute phone consultation · Adults 18+ throughout Georgia.
Our team sends the eVisit link. Payment is collected through eVisit after the visit. If our physician determines that the patient does not qualify, we will refund any consultation fee paid.
See pricing and fees, our consultation refund policy, and booking assistance.
This page provides general education and does not replace personalized medical advice, diagnosis, or treatment.